OBJECTIVE: CD44 (Cluster Differentiation 44) is an adhesional molecule postulated to play a role in tumor-cell invasion and metastasis. We have evaluated the correlation between the expression of CD44 variant 6 molecule and the prognostic factors in early stage cervical cancer. METHODS: Total sixty five samples of cervical tumor (23 samples of carcinoma in situ, 19 samples of FIGO stage Ia1, 9 samples of stage Ia2, 15 samples of stage Ib1) were immunohistochemically stained for detecting CD44V6 molecule, and which were compared with FIGO stage, invasion depth, gland involvement, lymphovascular space invasion, and keratinized type. RESULTS: CD44V6 was detected in 60 cases (92.3%). Immunoreactivity was decreased in more than 5 mm stromal invasion depth group (p=0.009), and there were no difference in carcinoma in situ, stage Ia1, and stage Ia2. There were no correlation between the expression of CD44 variant 6 molecule and the FIGO stage, gland involvement, lymphovascular space invasion, and keratinized type. CONCLUSION: CD44V6 expression does correlate with early stromal invasion, but does not correlate with other prognostic factors in cervical cancer. CD44V6 expression may play important role in progression of early cervical cancer.
Carcinoma in Situ ; Neoplasm Metastasis ; Uterine Cervical Neoplasms*

No abstract available.
Lymph Nodes ; Neoplasm Metastasis ; Uterine Cervical Neoplasms

No abstract available.
Humans ; Lymph Nodes ; Neoplasm Metastasis ; Uterine Cervical Neoplasms

Malignant mixed mullerian tumors (MMMT) are uncommon neoplasms of the female genital tract that histologically consist of malignant epithelial components and stromal components. Most MMMTs are found in postmenopausal women. The clinical course is very poor due to frequent metastasis and recurrence. Among the carcinogenic epidemiologic predisposing factors, the relationship of previous pelvic irradiation to subsequent development of a malignant mixed mullerian tumor has been reported in recent years. We are reporting a case of MMMT of the uterus which occured in a woman who received radiation therapy for cervical cancer 11 years before the present date.
Causality ; Female ; Humans ; Neoplasm Metastasis ; Recurrence ; Uterine Cervical Neoplasms* ; Uterus

Female ; Humans ; Neoplasm Metastasis ; Uterine Cervical Neoplasms ; pathology

No abstract available.
Antigens, Neoplasm ; Carcinoma, Squamous Cell ; Serpins ; Uterine Cervical Neoplasms

We experienced a case in which yeasts in blood sample from a patient with cervical cancer with hepatic metastasis and multiple intraperitoneal cysts interfered with platelet morphology flag in automated blood analyzer. The peripheral blood smear was performed to confirm the flag and revealed intracellular and extracellular yeasts, which were subsequently identified as Candida parapsilosis by blood culture.
Blood Platelets ; Candida ; Humans ; Neoplasm Metastasis ; Uterine Cervical Neoplasms ; Yeasts

Adenosarcoma/surgery* ; Female ; Heart Neoplasms ; Humans ; Neoplasm Metastasis ; Uterine Cervical Neoplasms ; Uterine Neoplasms/surgery*

The overall survival of patients with cervical cancer has improved due to detection at an early stage and availability of comprehensive treatments in China. As patients' lives prolonged, it is important to understand their health-related quality of life (QoL) during and after treatment. We used the EQ-5D questionnaire to assess QoL of 194 patients with cervical lesions at Sichuan University West China Second Hospital between May 2010 and January 2011. Patients were surveyed before primary treatment and at 1, 3, and 6 months after primary treatment. Results showed a consistent decline in EQ-5D scores in the spectrum of cervical lesions at each time point after treatment (all P < 0.05). For patients with precursor lesions, there was an increasing trend along the timeline of treatment (P < 0.01). For patients with early-stage cervical cancer, EQ-5D scores declined in the first month (P = 0.01) and gradually increased to higher levels at 6 months post-treatment than those before treatment (P < 0.01). EQ-5D scores followed a similar trend in patients with advanced cervical cancer (P = 0.04), though they did not statistically rebound after 6 months (0.84 ± 0.19 vs. 0.86 ± 0.11, P = 0.62). Regarding advanced cervical cancer, EQ-5D scores for women above 40 years of age appeared to recover more rapidly and reached higher levels than those for women below 40 years (P = 0.03). Caution and extra care are recommended in the early period of cervical cancer treatment given the slight deterioration in the QoL, and in particular, for younger cervical cancer patients. Our study implies that health care providers may need to improve the health-related QoL of cervical cancer patients.
Age Factors ; China ; Female ; Humans ; Neoplasm Staging ; Prospective Studies ; Quality of Life ; Surveys and Questionnaires ; Uterine Cervical Dysplasia ; Uterine Cervical Neoplasms

Objective: To explore the relationship between the expression of the T-cell activation suppressor-immunoglobulin variable region (VISTA) and the development of cervical squamous cell carcinoma (CSCC), and the impact on the prognosis of CSCC patients. Methods: Cervical tissue samples from 116 CSCC, including 23 cervical intraepithelial neoplasia (CIN) grade I, 23 CIN grade Ⅱ-Ⅲ, and 23 chronic cervicitis patients, were collected from the First Hospital of Soochow University between March 2014 and April 2019. The expression of VISTA in each group was detected by immunohistochemistry (IHC). Survival data of CSCC patients were obtained by follow-up. The survival analysis was performed by Kaplan-Meier method, and survival differences between groups were compared by Log rank test. Prognostic impact factors were analyzed using a multifactorial Cox proportional hazards model. Results: The positive rate of VISTA expression in CSCC group was 32.8% (38/116), and which of grade Ⅱ-Ⅲ was 17.4% (4/23). VISTA expression results showed no positive expression patients in the cervical intraepithelial neoplasia grade I and chronic cervicitis groups. The differences between the CSCC group and other groups were statistically significant (P<0.01). In 116 CSCC patients, VISTA expression was associated with International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis (P<0.01). The mean survival time of patients in the VISTA positive expression group was 30.7 months, and the 3-year survival rate was 44.7% (17/38). However, the mean survival time of the patients in the VISTA negative expression group was 49.1 months, and the 3-year survival rate was 87.2% (68/78). The Cox regression model found that VISTA expression positivity (P=0.001) and FIGO stage (P=0.047) were prognostic factors for CSCC, and patients with VISTA-positive CSCC had a 4.130-fold risk of death higher than those with VISTA-negative expression. Conclusions: The VISTA protein is highly expressed in CSCC tissues, and its expression level is closely related to the occurrence and development of CSCC. The expression of VISTA can be used as an independent predictor of CSCC prognosis and can provide a strong basis for the treatment of CSCC with immune checkpoint inhibitors.
Female ; Humans ; Carcinoma, Squamous Cell/pathology* ; Clinical Relevance ; Neoplasm Staging ; Prognosis ; Uterine Cervical Dysplasia/pathology* ; Uterine Cervical Neoplasms/pathology* ; Uterine Cervicitis/pathology*